B
165.43
-0.02 (-0.01%)
| Penutupan Terdahulu | 165.45 |
| Buka | 168.10 |
| Jumlah Dagangan | 77,497 |
| Purata Dagangan (3B) | 190,337 |
| Modal Pasaran | 6,611,461,120 |
| Harga / Pendapatan (P/E Ke hadapan) | 227.27 |
| Harga / Buku (P/B) | 8.57 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 May 2026 |
| EPS Cair (TTM) | -1.36 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.37% |
| Nisbah Semasa (MRQ) | 25.98 |
| Aliran Tunai Operasi (OCF TTM) | -29.23 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.42 M |
| Pulangan Atas Aset (ROA TTM) | -22.23% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.43% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Belite Bio, Inc | Menaik | Menaik |
AISkor Stockmoo
0.5
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -2.0 |
| Purata | 0.50 |
|
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 53.93% |
| % Dimiliki oleh Institusi | 0.75% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Darwin Global Management, Ltd. | 31 Dec 2025 | 3,027,704 |
| Western Standard Llc | 31 Dec 2025 | 60,026 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 266.00 (Cantor Fitzgerald, 60.79%) | Beli |
| Median | 200.50 (21.20%) | |
| Rendah | 195.00 (B of A Securities, 17.88%) | Beli |
| Purata | 215.50 (30.27%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 166.53 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Cantor Fitzgerald | 03 Mar 2026 | 266.00 (60.79%) | Beli | 167.88 |
| HC Wainwright & Co. | 03 Mar 2026 | 200.00 (20.90%) | Beli | 167.88 |
| 28 Jan 2026 | 185.00 (11.83%) | Beli | 165.64 | |
| Morgan Stanley | 03 Mar 2026 | 201.00 (21.50%) | Beli | 167.88 |
| B of A Securities | 26 Jan 2026 | 195.00 (17.87%) | Beli | 162.47 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CHEN WAN-SHAN | - | 181.17 | -1,100 | -199,287 |
| CHUANG HAO-YUAN | - | 181.17 | -6,200 | -1,123,254 |
| LIN YU-HSIN | - | 181.17 | -9,200 | -1,666,764 |
| MATA NATHAN L. | - | 168.76 | -1,000 | -168,760 |
| Jumlah Keseluruhan Kuantiti Bersih | -17,500 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -3,158,065 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 178.07 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MATA NATHAN L. | Pegawai | 15 Apr 2026 | Jual automatik (-) | 1,000 | 168.76 | 168,760 |
| CHUANG HAO-YUAN | Pegawai | 09 Apr 2026 | Jual automatik (-) | 6,200 | 181.17 | 1,123,254 |
| LIN YU-HSIN | Pegawai | 09 Apr 2026 | Jual automatik (-) | 9,200 | 181.17 | 1,666,764 |
| CHEN WAN-SHAN | Pengarah | 09 Apr 2026 | Jual automatik (-) | 1,100 | 181.17 | 199,287 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 29 Jan 2026 | Pengumuman | Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO) |
| 27 Jan 2026 | Pengumuman | Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |